News
SNTI
1.085
+17.36%
0.161
Weekly Report: what happened at SNTI last week (0615-0619)?
Weekly Report · 2d ago
SENTI BIOSCIENCES - OFFERING 15.97 MLN SHARES OF COMMON STOCK FOR RESALE BY SELLING SECURITYHOLDER - SEC FILING
Reuters · 5d ago
Weekly Report: what happened at SNTI last week (0608-0612)?
Weekly Report · 06/15 09:26
Weekly Report: what happened at SNTI last week (0601-0605)?
Weekly Report · 06/08 09:25
Weekly Report: what happened at SNTI last week (0525-0529)?
Weekly Report · 06/01 09:26
Senti Biosciences Details New Direct Financial Obligation
TipRanks · 05/26 21:05
Senti Biosciences unit issues USD 10 million senior secured convertible notes to Celadon Partners SPV 24
PUBT · 05/26 20:03
Weekly Report: what happened at SNTI last week (0518-0522)?
Weekly Report · 05/25 09:27
Weekly Report: what happened at SNTI last week (0511-0515)?
Weekly Report · 05/18 09:27
Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)
TipRanks · 05/17 16:40
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure
TipRanks · 05/16 06:00
Senti Biosciences Is Maintained at Buy by Chardan Capital
Dow Jones · 05/15 12:27
Senti Biosciences Price Target Raised to $12.00/Share From $11.00 by Chardan Capital
Dow Jones · 05/15 12:27
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12
Benzinga · 05/15 12:17
Analyst Maintains Buy on Senti Biosciences, Keeps $12 Price Target on Strengthened Clinical, Regulatory, and Financial Position
TipRanks · 05/15 10:25
Senti Biosciences Q1 FY26 net loss narrows to $4.22 million; revenue rises to $16,000
PUBT · 05/14 20:22
Senti Biosciences GAAP EPS of -$0.14, revenue of $0.01M
Seeking Alpha · 05/14 18:25
Senti Bio completes Type B RMAT meeting with FDA on SENTI-202
TipRanks · 05/14 13:42
Senti Bio reports Q1 EPS (14c), consensus (36c)
TipRanks · 05/14 13:38
Senti Biosciences Advances SENTI-202 With New FDA Support
TipRanks · 05/14 13:18
More
Webull provides a variety of real-time SNTI stock news. You can receive the latest news about Senti Biosciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SNTI
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.